Stockscreener 앱 받기
1.19
0.83%
-0.01
시간 외 거래:
1.18
-0.01
-0.84%
전일 마감가:
$1.20
열려 있는:
$1.19
하루 거래량:
600.57K
Relative Volume:
0.74
시가총액:
$36.74M
수익:
$680.00K
순이익/손실:
$-75.33M
주가수익비율:
-0.1923
EPS:
-6.1898
순현금흐름:
$-57.38M
1주 성능:
+9.17%
1개월 성능:
+4.39%
6개월 성능:
-33.89%
1년 성능:
-27.44%
1일 변동 폭
$1.18
$1.26
1주일 범위
$1.08
$1.27
52주 변동 폭
$1.01
$8.08
바이오엑셀 테라퓨틱스 Stock (BTAI) Company Profile
명칭
Bioxcel Therapeutics Inc
전화
203-643-8060
주소
555 LONG WHARF DRIVE, NEW HAVEN, CT
Compare BTAI vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
1.19 | 35.82M | 680.00K | -75.33M | -57.38M | -6.1898 |
TAK
Takeda Pharmaceutical Co Adr
|
15.42 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.87 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.56 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.26 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
551.47 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
바이오엑셀 테라퓨틱스 Stock (BTAI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-17 | 개시 | Rodman & Renshaw | Buy |
| 2024-02-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-08-15 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2023-07-17 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-03-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-12-01 | 업그레이드 | Goldman | Sell → Neutral |
| 2022-07-07 | 개시 | Mizuho | Buy |
| 2022-04-06 | 재확인 | BofA Securities | Buy |
| 2021-11-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-04-09 | 개시 | Berenberg | Buy |
| 2021-02-01 | 개시 | UBS | Buy |
| 2020-10-30 | 개시 | Goldman | Buy |
| 2020-09-02 | 개시 | Jefferies | Buy |
| 2020-08-17 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-04 | 개시 | Guggenheim | Buy |
| 2020-04-01 | 개시 | BofA/Merrill | Buy |
| 2020-02-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-08 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-12 | 개시 | SunTrust | Buy |
모두보기
바이오엑셀 테라퓨틱스 주식(BTAI)의 최신 뉴스
BTAI News | BIOXCEL THERAPEUTICS INC (NASDAQ:BTAI) - ChartMill
BTAI Stock Gained 5% TodayWhat's The Latest On Its Opioid Withdrawal Treatment? - Stocktwits
Attention BioXcel Shareholders: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Securities Fraud Class Action Lawsuit Filed against BioXcel Therapeutics, Inc. (BTAI) and Encourages Investors to Contact the Firm - TMX Newsfile
What makes BioXcel Therapeutics (BTAI) a new buy stock - MSN
BioXcel Deadline Alert - TMX Newsfile
What Makes BioXcel Therapeutics (BTAI) a New Buy Stock - Yahoo Finance
BioXcel Shareholder Action Reminder - TMX Newsfile
BTAI Technical Analysis & Stock Price Forecast - Intellectia AI
BioXcel presents data on at-home agitation treatment trial By Investing.com - Investing.com India
BioXcel Therapeutics Presents New Data from Serenity At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia - marketscreener.com
BioXcel presents data on at-home agitation treatment trial - Investing.com
BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting - The Manila Times
BioXcel Therapeutics Presents New Data from SERENITY - GlobeNewswire
BioXcel Therapeutics | 424B5: Prospectus - Moomoo
BioXcel Therapeutics Company Profile & Introduction - Moomoo
BioXcel Therapeutics CEO Mehta sells $21,108 in company stock By Investing.com - Investing.com Nigeria
BioXcel Therapeutics chief legal officer sells $7,111 in stock By Investing.com - Investing.com Nigeria
BioXcel CFO Richard Steinhart sells $7,426 of stock By Investing.com - Investing.com India
BioXcel Therapeutics CSO Frank Yocca sells $7,426 in company stock By Investing.com - Investing.com Nigeria
BioXcel Therapeutics CEO Mehta sells $21,108 in company stock - Investing.com India
BioXcel CFO Richard Steinhart sells $7,426 of stock - Investing.com UK
BioXcel Therapeutics chief legal officer sells $7,111 in stock - Investing.com
BioXcel Therapeutics CSO Frank Yocca sells $7,426 in company stock - Investing.com
BioXcel Therapeutics (BTAI) CSO exercises 17,500 RSUs, sells 6,845 shares for tax payment - Stock Titan
BioXcel Therapeutics (BTAI) executive sells shares after RSU vesting for taxes - Stock Titan
BioXcel (BTAI) CFO exercises 17,500 RSUs and sells 6,845 shares for taxes - Stock Titan
BioXcel Therapeutics (BTAI) CEO sells shares to cover RSU tax obligations - Stock Titan
BioXcel Shareholder Notice - TMX Newsfile
BioXcel Therapeutics (BTAI) Form 144: 19,419 RSUs vested, 30.9M shares outstanding - Stock Titan
BioXcel Therapeutics (NASDAQ: BTAI) notice to sell 6,560 vested restricted shares - Stock Titan
BioXcel Therapeutics (BTAI) Rule 144: 6,845 shares from vested RSUs - Stock Titan
[144] BioXcel Therapeutics, Inc. SEC Filing - Stock Titan
Is BioXcel Therapeutics (BTAI) Overvalued After Q1 2026? EPS Not - GuruFocus
BioXcel Therapeutics, Inc. (BTAI) reports Q1 loss, lags revenue estimates - MSN
Is BioXcel Therapeutics (BTAI) Overvalued After Q1 2026 Results? - GuruFocus
BioXcel Therapeutics Reports Q1 2026 Results, FDA Accepts IGALMI sNDA for At-Home Use, and Explores Strategic Options - Minichart
BioXcel Therapeutics (BTAI) Reports First Quarter Revenue and Re - GuruFocus
BioXcel Therapeutics 1Q Loss $12.7M >BTAI - Moomoo
Press Release: BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results - Moomoo
Armistice Capital reports 7.05% stake in BioXcel (NASDAQ: BTAI) - Stock Titan
바이오엑셀 테라퓨틱스 (BTAI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
바이오엑셀 테라퓨틱스 주식 (BTAI) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Rodriguez Javier | See Remarks |
May 20 '26 |
Sale |
1.08 |
6,560 |
7,111 |
26,803 |
| Steinhart Richard I | Chief Financial Officer |
May 20 '26 |
Sale |
1.08 |
6,845 |
7,427 |
26,300 |
| Mehta Vimal | CEO and President |
May 20 '26 |
Sale |
1.09 |
19,419 |
21,108 |
69,598 |
0.95%
1.13%
자본화:
|
볼륨(24시간):